As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

NEW YORK – Novartis on Thursday announced it has acquired Kate Therapeutics to bolster its capabilities to develop gene therapies for inherited neuromuscular diseases. In the transaction valued at ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) as a treatment for advanced HER2-positive biliary tract cancer.

NEW YORK – Neuron23 this week detailed the design of its global Phase II trial, dubbed NEULARK, in which it is investigating a precision treatment strategy in early Parkinson's disease. Within the ...

The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.